Quality of Life and the Experience of Living with Early-Stage Alzheimer's Disease
Villarejo-Galende, Alberto (Instituto de Salud Carlos III)
García-Arcelay, E. (Roche Farma)
Piñol-Ripoll, G. (Hospital de Santa Maria (Lleida, Catalunya))
Del Olmo-Rodríguez, A. (Hospital Universitari Doctor Peset (València))
Viñuela, F. (Hospital Universitario Virgen Macarena)
Boada, M. (Universitat Internacional de Catalunya)
Franco-Macías, E. (Instituto de Biomedicina de Sevilla)
Ibañez De La Peña, A. (Policlínica Guipúzcoa)
Riverol, M. (Universidad de Navarra)
Puig-Pijoan, Albert (Institut Hospital del Mar d'Investigacions Mèdiques)
Abizanda-Soler, Pedro (Complejo Hospitalario Universitario de Albacete)
Arroyo, Rafael (Hospital Universitario Quirónsalud)
Baquero-Toledo, M. (Hospital Universitari i Politècnic La Fe (València))
Feria-Vilar, Inmaculada (Complejo Hospitalario Universitario de Albacete)
Balasa, M. (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Berbel, Á. (Hospital Central de la Cruz Roja)
Rodríguez-Rodríguez, E. (Universidad de Cantabria)
Vieira-Campos, A. (Hospital Universitario de la Princesa)
García-Ribas, G. (Instituto de Investigación Hospital 12 de Octubre)
Rodrigo-Herrero, S. (Instituto de Investigación Hospital 12 de Octubre)
Terrancle, Á. (Roche Farma)
Prefasi, D. (Roche Farma)
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau)
Maurino, J. (Roche Farma)
Universitat Autònoma de Barcelona

Date:	2022
Abstract:	Background: There is a need to better understand the experience of patients living with Alzheimer's disease (AD) in the early stages. Objective: The aim of the study was to evaluate the perception of quality of life in patients with early-stage AD. Methods: A multicenter, non-interventional study was conducted including patients of 50-90 years of age with prodromal or mild AD, a Mini-Mental State Examination (MMSE) score ≥22, and a Clinical Dementia Rating-Global score (CDR-GS) of 0. 5. -1. 0. The Quality of Life in Alzheimer 's Disease (QoL-AD) questionnaire was used to assess health-related quality of life. A battery of self-report instruments was used to evaluate different psychological and behavioral domains. Associations between the QoL-AD and other outcome measures were analyzed using Spearman's rank correlations. Results: A total of 149 patients were included. Mean age (SD) was 72. 3 (7. 0) years and mean disease duration was 1. 4 (1. 8) years. Mean MMSE score was 24. 6 (2. 1). The mean QoL-AD score was 37. 9 (4. 5). Eighty-three percent (n = 124) of patients had moderate-to-severe hopelessness, 22. 1% (n = 33) had depressive symptoms, and 36. 9% (n = 55) felt stigmatized. The quality of life showed a significant positive correlation with self-efficacy and negative correlations with depression, emotional and practical consequences, stigma, and hopelessness. Conclusion: Stigma, depressive symptoms, and hopelessness are frequent scenarios in AD negatively impacting quality of life, even in a population with short disease duration and minimal cognitive impairment.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Alzheimer's disease ; Amyloid ; Biomarkers ; Cerebrospinal fluid ; Magnetic resonance imaging ; Tau proteins ; White matter hyperintensities ; White matter lesions
Published in:	Journal of Alzheimer's disease, Vol. 90 Núm. 2 (2022) , p. 719-726, ISSN 1875-8908

DOI: 10.3233/JAD-220696
PMID: 36155523

8 p, 208.5 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles